35311709|t|Pharmacogenetic Analyses of Therapeutic Effects of Lipophilic Statins on Cognitive and Functional Changes in Alzheimer's Disease.
35311709|a|BACKGROUND: Pharmacogenetic effects of statins on clinical changes in Alzheimer's disease (AD) could be mediated by epistatic interactions among relevant genetic variants involved in cholesterol metabolism. OBJECTIVE: To investigate associations of HMGCR (rs3846662), NR1H2 (rs2695121), or CETP (rs5882&rs708272) with cognitive and functional changes in AD, with stratification according to APOEe4 carrier status and lipid-lowering treatment with lipophilic statins. METHODS: Consecutive outpatients with late-onset AD were screened with cognitive tests, while caregivers scored functionality and global ratings, with prospective neurotranslational associations documented for one year. RESULTS: Considering n = 190:142 had hypercholesterolemia, 139 used lipophilic statins; minor allele frequencies were 0.379 (rs2695121-T:46.3% heterozygotes), 0.368 (rs5882-G:49.5% heterozygotes), and 0.371 (rs708272-A:53.2% heterozygotes), all in Hardy-Weinberg equilibrium. For APOEe4 carriers: rs5882-GG protected from cognitive decline; rs5882-AA caused faster cognitive decline; carriers of rs2695121-CC or rs5882-AA were more susceptible to harmful cognitive effects of lipophilic statins; carriers of rs5882-GG or rs708272-AG had functional benefits when using lipophilic statins. APOEe4 non-carriers resisted any cognitive or functional effects of lipophilic statins, while invariability of rs3846662 (all AA) prevented the assessment of HMGCR effects. When assessing CETP haplotypes only: rs5882-GG protected from cognitive and functional decline, regardless of lipophilic statin therapy; lipophilic statins usually caused cognitive and functional harm to carriers of rs5882-A and/or rs708272-A; lipophilic statins benefitted cognition and functionality of carriers of rs5882-G and/or rs708272-G. CONCLUSION: Reportedly protective variants of CETP and NR1H2 also slowed cognitive and functional decline particularly for APOEe4 carriers, and regardless of cholesterol variations, while therapy with lipophilic statins might affect carriers of specific genetic variants.
35311709	73	82	Cognitive	Disease	MESH:D003072
35311709	109	128	Alzheimer's Disease	Disease	MESH:D000544
35311709	200	219	Alzheimer's disease	Disease	MESH:D000544
35311709	221	223	AD	Disease	MESH:D000544
35311709	313	324	cholesterol	Chemical	MESH:D002784
35311709	379	384	HMGCR	Gene	3156
35311709	386	395	rs3846662	SNP	tmVar:rs3846662;VariantGroup:0;CorrespondingGene:3156;RS#:3846662;CorrespondingSpecies:9606
35311709	398	403	NR1H2	Gene	7376
35311709	405	414	rs2695121	SNP	tmVar:rs2695121;VariantGroup:2;CorrespondingGene:7376;RS#:2695121;CorrespondingSpecies:9606
35311709	420	424	CETP	Gene	1071
35311709	426	432	rs5882	SNP	tmVar:rs5882;VariantGroup:1;CorrespondingGene:1071;RS#:5882;CorrespondingSpecies:9606
35311709	433	441	rs708272	SNP	tmVar:rs708272;VariantGroup:3;CorrespondingGene:1071;RS#:708272;CorrespondingSpecies:9606
35311709	448	457	cognitive	Disease	MESH:D003072
35311709	484	486	AD	Disease	MESH:D000544
35311709	547	552	lipid	Chemical	MESH:D008055
35311709	646	648	AD	Disease	MESH:D000544
35311709	668	677	cognitive	Disease	MESH:D003072
35311709	854	874	hypercholesterolemia	Disease	MESH:D006937
35311709	942	951	rs2695121	SNP	tmVar:rs2695121;VariantGroup:2;CorrespondingGene:7376;RS#:2695121;CorrespondingSpecies:9606
35311709	983	989	rs5882	SNP	tmVar:rs5882;VariantGroup:1;CorrespondingGene:1071;RS#:5882;CorrespondingSpecies:9606
35311709	1025	1033	rs708272	SNP	tmVar:rs708272;VariantGroup:3;CorrespondingGene:1071;RS#:708272;CorrespondingSpecies:9606
35311709	1114	1120	rs5882	SNP	tmVar:rs5882;VariantGroup:1;CorrespondingGene:1071;RS#:5882;CorrespondingSpecies:9606
35311709	1139	1156	cognitive decline	Disease	MESH:D003072
35311709	1158	1164	rs5882	SNP	tmVar:rs5882;VariantGroup:1;CorrespondingGene:1071;RS#:5882;CorrespondingSpecies:9606
35311709	1182	1199	cognitive decline	Disease	MESH:D003072
35311709	1213	1222	rs2695121	SNP	tmVar:rs2695121;VariantGroup:2;CorrespondingGene:7376;RS#:2695121;CorrespondingSpecies:9606
35311709	1229	1235	rs5882	SNP	tmVar:rs5882;VariantGroup:1;CorrespondingGene:1071;RS#:5882;CorrespondingSpecies:9606
35311709	1272	1281	cognitive	Disease	MESH:D003072
35311709	1325	1331	rs5882	SNP	tmVar:rs5882;VariantGroup:1;CorrespondingGene:1071;RS#:5882;CorrespondingSpecies:9606
35311709	1338	1346	rs708272	SNP	tmVar:rs708272;VariantGroup:3;CorrespondingGene:1071;RS#:708272;CorrespondingSpecies:9606
35311709	1438	1447	cognitive	Disease	MESH:D003072
35311709	1516	1525	rs3846662	SNP	tmVar:rs3846662;VariantGroup:0;CorrespondingGene:3156;RS#:3846662;CorrespondingSpecies:9606
35311709	1563	1568	HMGCR	Gene	3156
35311709	1593	1597	CETP	Gene	1071
35311709	1615	1621	rs5882	SNP	tmVar:rs5882;VariantGroup:1;CorrespondingGene:1071;RS#:5882;CorrespondingSpecies:9606
35311709	1640	1672	cognitive and functional decline	Disease	MESH:D003072
35311709	1749	1758	cognitive	Disease	MESH:D003072
35311709	1794	1800	rs5882	SNP	tmVar:rs5882;VariantGroup:1;CorrespondingGene:1071;RS#:5882;CorrespondingSpecies:9606
35311709	1810	1818	rs708272	SNP	tmVar:rs708272;VariantGroup:3;CorrespondingGene:1071;RS#:708272;CorrespondingSpecies:9606
35311709	1895	1901	rs5882	SNP	tmVar:rs5882;VariantGroup:1;CorrespondingGene:1071;RS#:5882;CorrespondingSpecies:9606
35311709	1911	1919	rs708272	SNP	tmVar:rs708272;VariantGroup:3;CorrespondingGene:1071;RS#:708272;CorrespondingSpecies:9606
35311709	1969	1973	CETP	Gene	1071
35311709	1978	1983	NR1H2	Gene	7376
35311709	1996	2028	cognitive and functional decline	Disease	MESH:D003072
35311709	2081	2092	cholesterol	Chemical	MESH:D002784
35311709	Positive_Correlation	MESH:D003072	RS#:5882;CorrespondingGene:1071
35311709	Association	MESH:D003072	1071
35311709	Association	MESH:D003072	RS#:3846662;CorrespondingGene:3156
35311709	Association	MESH:D003072	1071
35311709	Association	MESH:D003072	3156

